These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 3978346)

  • 1. The impact of lithium in South-west Scotland. II. A longitudinal study.
    Morrison DP; McCreadie RG
    Br J Psychiatry; 1985 Jan; 146():74-7. PubMed ID: 3978346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of lithium in South-west Scotland. I. Demographic and clinical findings.
    McCreadie RG; Morrison DP
    Br J Psychiatry; 1985 Jan; 146():70-4. PubMed ID: 3872149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prophylactic lithium treatment: treatment response, and patient attitudes toward illness and treatment.
    Schmidt S; Ludwig W; Seibold S; Greil W
    Pharmacopsychiatry; 1988 Nov; 21(6):274-5. PubMed ID: 3244750
    [No Abstract]   [Full Text] [Related]  

  • 4. Outcome of lithium prophylaxis: a prospective follow-up of affective disorder patients assigned to high and low serum lithium levels.
    Vestergaard P; Licht RW; Brodersen A; Rasmussen NA; Christensen H; Arngrim T; Grønvall B; Kristensen E; Poulstrup I
    Acta Psychiatr Scand; 1998 Oct; 98(4):310-5. PubMed ID: 9821453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of lithium in South-West Scotland. III. The discontinuation of lithium.
    McCreadie RG; McCormick M; Morrison DP
    Br J Psychiatry; 1985 Jan; 146():77-80. PubMed ID: 3978347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prophylactic lithium in affective disorders. Controlled trial.
    Coppen A; Noguera R; Bailey J; Burns BH; Swani MS; Hare EH; Gardner R; Maggs R
    Lancet; 1971 Aug; 2(7719):275-9. PubMed ID: 4104974
    [No Abstract]   [Full Text] [Related]  

  • 7. Further evidence for a possible association between serotonin transporter gene and lithium prophylaxis in mood disorders.
    Serretti A; Malitas PN; Mandelli L; Lorenzi C; Ploia C; Alevizos B; Nikolaou C; Boufidou F; Christodoulou GN; Smeraldi E
    Pharmacogenomics J; 2004; 4(4):267-73. PubMed ID: 15111989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lithium in the prophylactic treatment of recurrent affective disorders.
    Kua EH; Lee SL; Chee KT
    Singapore Med J; 1982 Oct; 23(5):262-4. PubMed ID: 7157005
    [No Abstract]   [Full Text] [Related]  

  • 9. Autosomal recessive inheritance of affective disorders in families of responders to lithium prophylaxis?
    Alda M; Grof E; Cavazzoni P; Duffy A; Martin R; Ravindran L; Grof P
    J Affect Disord; 1997 Jul; 44(2-3):153-7. PubMed ID: 9241575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of affective illness on gene expression: implications for early and long-term prophylaxis.
    Post RM
    Clin Neuropharmacol; 1992; 15 Suppl 1 Pt A():452A-453A. PubMed ID: 1498913
    [No Abstract]   [Full Text] [Related]  

  • 11. Mood disorders: pharmacologic prevention of recurrences. A National Institutes of Health consensus report synopsis.
    Hull RH
    Indiana Med; 1985 Jan; 78(1):36-7. PubMed ID: 3968418
    [No Abstract]   [Full Text] [Related]  

  • 12. [Prophylactic treatment of mood disorders: cost effectiveness analysis comparing lithium and carbamazepine].
    Dardennes R; Lafuma A; Watkins S
    Encephale; 1999; 25(5):391-400. PubMed ID: 10598301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between prophylactic effect of lithium therapy and family history of affective disorders.
    Engström C; Aström M; Nordqvist-Karlsson B; Adolfsson R; Nylander PO
    Biol Psychiatry; 1997 Sep; 42(6):425-33. PubMed ID: 9285078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loudness dependence of primary auditory-cortex-evoked activity as predictor of therapeutic outcome to prophylactic lithium treatment in affective disorders--a retrospective study.
    Juckel G; Mavrogiorgou P; Bredemeier S; Gallinat J; Frodl T; Schulz C; Möller HJ; Hegerl U
    Pharmacopsychiatry; 2004 Mar; 37(2):46-51. PubMed ID: 15048610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lithium prophylaxis of depression in unipolar, bipolar II, and cyclothymic patients.
    Peselow ED; Dunner DL; Fieve RR; Lautin A
    Am J Psychiatry; 1982 Jun; 139(6):747-52. PubMed ID: 6805339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is there a loss of efficacy of lithium in patients treated for over 20 years?
    Berghöfer A; Müller-Oerlinghausen B
    Neuropsychobiology; 2000; 42 Suppl 1():46-9. PubMed ID: 11093072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapy of affective disorders.
    Alexander B; Cook B
    Prim Care; 1990 Sep; 17(3):565-88. PubMed ID: 2236337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carbamazepine as adjunct or alternative to lithium in the prophylaxis of recurrent affective disorders.
    Fritze J; Beneke M; Lanczik M; Schneider B; Walden J
    Pharmacopsychiatry; 1994 Sep; 27(5):181-5. PubMed ID: 7838887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Who responds to prophylactic lithium therapy?
    Abou-Saleh MT
    Br J Psychiatry Suppl; 1993 Sep; (21):20-6. PubMed ID: 8217063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced plasma cyclic AMP level during prophylactic lithium treatment in patients with affective disorders.
    Arató M; Rihmer Z; Felszeghy K
    Biol Psychiatry; 1980 Apr; 15(2):319-22. PubMed ID: 6251928
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.